Lexicon Pharmaceuticals vs SIGA Technologies
LXRX and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SIGA compare
Lexicon Pharmaceuticals is the larger company, worth 4.0 times as much as SIGA Technologies ($796M against $197M).
Lexicon Pharmaceuticals grew revenue faster over the last twelve months (−45.6% versus −69.6% for SIGA Technologies).
SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of 1.3% compared with −162% at Lexicon Pharmaceuticals.
SIGA Technologies pays a dividend yielding 21.9%; Lexicon Pharmaceuticals does not pay one.
SIGA Technologies scores higher on the StockData Score (14 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SIGA |
|---|---|---|
| Size and price | ||
| Market cap | $796M | $197M |
| Share price | $1.79 | $2.74 |
| Change, 1 year | 16.2% | −55.9% |
| Change, 5 years | −63.9% | −70.4% |
| Beta (5Y) | 1.76 | 1.08 |
| Employees | 81 | 49 |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 20.7× | 3.8× (better) |
| P/B | 4.9× | 1.2× (better) |
| Fair value | $0.871 | $6.01 |
| Margin of safety | −106% | 54.4% (better) |
| Growth | ||
| Revenue growth (TTM) | −45.6% (better) | −69.6% |
| Revenue growth, 5Y average | 15.7% (better) | −5.4% |
| Net income growth (TTM) | – | −99.1% |
| EPS growth (TTM) | – | −100% |
| EPS growth, 5Y average | – | −14.7% |
| Profitability | ||
| Gross margin | 98.9% (better) | 54.0% |
| Operating margin | −147% | −14.2% (better) |
| Net margin | −162% | 1.3% (better) |
| Return on equity | −43.9% | 0.37% (better) |
| Return on invested capital | −140% | −15.0% (better) |
| Financial health | ||
| Debt / equity | 0.32 (better) | 0.00 |
| Current ratio | 10.63 | 24.57 (better) |
| Altman Z-score | −5.60 | 13.18 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 21.9% |
| Payout ratio | – | 6325% |
| Years of dividend growth | – | 0 |
| Buyback yield | −8.9% | – |
| Shareholder yield | −8.9% | 21.9% (better) |
| Ownership | ||
| Held by institutions | 81.9% | 48.5% |
| Held by insiders | – | 1.9% |
| Insider net buying, 12 months | $2.8M | – |
| Short interest, % of float | – | 5.1% |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SIGA stock overview
- SIGA income statement
- SIGA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.